Hengrui Eyes International Expansion Amid Slowing Home Market
This article was originally published in PharmAsia News
Sustained price cuts and an ongoing compliance probe have slowed down domestic market growth, effectively pushing the Chinese domestic drug maker to venture out to the U.S., European markets and Japan.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
With gene editing making the news again after the recent Nobel Prize for CRISPR, China’s EdiGene has been raising new funds to accelerate its pipeline to the clinic, led by a potential one-time cure for thalassemia and helped by recent regulatory changes.